Raloxifene: Mechanism of Action, Effects on Bone Tissue, and Applicability in Clinical Traumatology Practice

Raloxifene, a member of the class of selective estrogen receptor modulators (SERM), reproduces the beneficial effects of estrogens on the skeletal systems, without the negative effects estrogens on breast and endometrium. This is a review article summarizing its mechanism, effects on bone and its applicability in traumatology clinical practice. In postmenopausal osteoporosis, this drug has been proven to decrease accelerated bone turnover, increase bone mineral density (BMD), and to structurally recover bone, decreasing the risk of vertebral fractures and the risk of non-vertebral fractures in patients with previous, severe vertebral fractures. Moreover, raloxifene appears to lower the risk of invasive breast cancer. Raloxifene would be efficacious in the prevention and treatment of postmenopausal osteoporosis. We can therefore conclude that raloxifene would be efficacious in the prevention and treatment of postmenopausal osteoporosis, while reducing the risk of breast cancer when used at the indicated dose of 60 mg/day and with a low incidence of side effects.

[1]  M. Whitehead,et al.  Long-term effects of transdermal and oral hormone replacement therapy on postmenopausal bone loss , 1994, Osteoporosis International.

[2]  P. Chambon,et al.  Functional domains of the human estrogen receptor , 1987, Cell.

[3]  D. Kiel,et al.  The effect of postmenopausal estrogen therapy on bone density in elderly women. , 1993, The New England journal of medicine.

[4]  C. Christiansen,et al.  Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women. , 1997, The New England journal of medicine.

[5]  L. Hartmann,et al.  Selective estrogen-receptor modulators -- mechanisms of action and application to clinical practice. , 2003, The New England journal of medicine.

[6]  A. LaCroix,et al.  Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. , 1998, JAMA.

[7]  S. Cummings,et al.  Continuing outcomes relevant to Evista: breast cancer incidence in postmenopausal osteoporotic women in a randomized trial of raloxifene. , 2004, Journal of the National Cancer Institute.

[8]  C. Christiansen,et al.  Six and Twelve Month Changes in Bone Turnover are Related to Reduction in Vertebral Fracture Risk During 3 Years of Raloxifene Treatment in Postmenopausal Osteoporosis , 2001, Osteoporosis International.

[9]  Jacques P. Brown,et al.  2002 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada. , 2002, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.

[10]  Fran Harris,et al.  Improvement in spine bone density and reduction in risk of vertebral fractures during treatment with antiresorptive drugs. , 2002, The American journal of medicine.

[11]  Norman Wolmark,et al.  Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. , 2006, JAMA.

[12]  M. Maricic,et al.  Raloxifene: Recent information on skeletal and non-skeletal effects , 2002, Current opinion in rheumatology.

[13]  J. Adachi,et al.  Early effects of raloxifene on clinical vertebral fractures at 12 months in postmenopausal women with osteoporosis. , 2002, Archives of internal medicine.

[14]  S. Corson.  Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes , 2006 .

[15]  J. Samet,et al.  Food and Drug Administration , 2007, BMJ : British Medical Journal.

[16]  C. Christiansen,et al.  Long-term effects of raloxifene on bone mineral density, bone turnover, and serum lipid levels in early postmenopausal women: three-year data from 2 double-blind, randomized, placebo-controlled trials. , 2000, Archives of internal medicine.

[17]  S. Martino,et al.  Safety assessment of raloxifene over eight years in a clinical trial setting* , 2005, Current medical research and opinion.

[18]  B. Riggs,et al.  Treatment of Established Postmenopausal Osteoporosis with Raloxifene: A Randomized Trial , 1998, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[19]  R. Langer,et al.  Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the Women's Health Initiative Randomized Trial. , 2003, JAMA.

[20]  M. Muñoz-Torres,et al.  Prevención y tratamiento de la osteoporosis , 2003 .

[21]  S. Cummings,et al.  The Effect of Raloxifene on Risk of Breast Cancer in Postmenopausal Women: Results From the MORE Randomized Trial , 2000 .

[22]  R. Turner,et al.  Raloxifene inhibits bone turnover and prevents further cancellous bone loss in adult ovariectomized rats with established osteopenia. , 1996, Endocrinology.

[23]  E. Barrett-Connor,et al.  Adult Weight Change and Risk of Postmenopausal Breast Cancer , 2006, The New England journal of medicine.

[24]  J. Frasor,et al.  Selective Estrogen Receptor Modulators , 2004, Cancer Research.

[25]  W. Gianni,et al.  Raloxifene modulates interleukin-6 and tumor necrosis factor-alpha synthesis in vivo: results from a pilot clinical study. , 2004, The Journal of clinical endocrinology and metabolism.

[26]  H. Bryant,et al.  Benzopyran selective estrogen receptor modulators (SERMs): Pharmacological effects and structural correlation with raloxifene , 1996 .

[27]  J. Scott,et al.  Raloxifene: a selective estrogen receptor modulator. , 1999, American family physician.

[28]  H. Bryant,et al.  A pharmacological review of raloxifene , 1996, Journal of Bone and Mineral Metabolism.

[29]  D. Black,et al.  Relationships Between Bone Mineral Density and Incident Vertebral Fracture Risk with Raloxifene Therapy , 2002, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[30]  R. Heaney,et al.  Is the paradigm shifting? , 2003, Bone.

[31]  H. Genant,et al.  Severity of prevalent vertebral fractures and the risk of subsequent vertebral and nonvertebral fractures: results from the MORE trial. , 2003, Bone.

[32]  M. H. Duncan.  Hormone replacement therapy Cardioprotective effect is genuine , 1994, British medical journal.

[33]  Richard Eastell,et al.  Relationship between changes in bone mineral density and vertebral fracture risk associated with risedronate: greater increases in bone mineral density do not relate to greater decreases in fracture risk. , 2004, Journal of clinical densitometry : the official journal of the International Society for Clinical Densitometry.

[34]  M. Klag,et al.  Plasma lipoprotein levels as predictors of cardiovascular death in women. , 1993, Archives of internal medicine.

[35]  H. Broxmeyer,et al.  Increased osteoclast development after estrogen loss: mediation by interleukin-6 , 1992 .

[36]  David A Hanley,et al.  2010 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada: summary , 2010, Canadian Medical Association Journal.

[37]  O. Johnell,et al.  Effect of raloxifene on the risk of new vertebral fracture in postmenopausal women with osteopenia or osteoporosis: a reanalysis of the Multiple Outcomes of Raloxifene Evaluation trial. , 2003, Bone.

[38]  Valerie Beral,et al.  Breast cancer and hormone-replacement therapy in the Million Women Study , 2003, The Lancet.

[39]  H. Broxmeyer,et al.  Increased osteoclast development after estrogen loss: mediation by interleukin-6. , 1992, Science.

[40]  A. Glasebrook,et al.  Identification of an Estrogen Response Element Activated by Metabolites of 17β-Estradiol and Raloxifene , 1996, Science.

[41]  C C Glüer,et al.  Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. , 1999, JAMA.

[42]  C. Turner,et al.  Raloxifene preserves bone strength and bone mass in ovariectomized rats. , 1994, Endocrinology.